Conclusion
RVEF by 3D echo is an effective tool to stratify patients at high risk for CAE after chemotherapy. The RVEF helped identifying late CAE and added incremental value to the analysis of clinical variables and LVGLS. Therefore, in patients with lymphoma treated with R-CHOP regimens, a 3-D echo-based imaging for LV and RV could be used to help tailor oncologic and cardiac treatment and reduce CAE.